EMA Authorised: Dyrupeg (pegfilgrastim) — CuraTeQ Biologics (Malta) Limited

View source ↗

Summary

Dyrupeg (pegfilgrastim) has been authorised by the EMA for neutropenia and cancer indications.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Neutropenia

Drugs mentioned

• Dyrupeg (pegfilgrastim)

Snippet

Status: Authorised. Therapeutic area: Neutropenia;Cancer. MAH: CuraTeQ Biologics (Malta) Limited. Decision date: 12/06/2026